Sutro Biopharma has filed a patent for an improved method of stabilizing freeze-dried bacterial extracts using a carbohydrate lyoprotectant. The extracts can be used in cell-free protein synthesis and the formulations can retain at least 70% protein synthesis activity when stored at room temperature. GlobalData’s report on Sutro Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sutro Biopharma, nanoparticle drug conjugates was a key innovation area identified from patents. Sutro Biopharma's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230167475A1) describes a freeze-dried bacterial extract for cell-free protein synthesis. The extract consists of dried, lysed bacterial components that can synthesize a target protein when rehydrated with a template nucleic acid encoding the protein. The extract also includes a carbohydrate composition in a specific ratio to the bacterial components, with the carbohydrate composition containing sucrose and a non-sucrose portion comprising mannitol, sorbitol, dextran, or a mixture of these substances.
The patent claims that the freeze-dried bacterial extract has several desirable properties. It has a low residual water content, with less than or equal to about 2.6% or 1.5% residual water. The extract also demonstrates high protein synthesis activity, even after being stored at room temperature for extended periods. After being stored for 25 days or more and then rehydrated, the extract retains at least 70% protein synthesis activity compared to a control extract. In some cases, the rehydrated extract can have at least 80% protein synthesis activity. The patent also mentions that the extract can be stored for 50 days or more or even 150 days or more before rehydration.
The freeze-dried bacterial extract can be used in methods for producing target proteins. By rehydrating the extract and combining it with a cell-free protein synthesis reaction mixture, the target protein can be synthesized. The patent also mentions that the target protein can include non-natural amino acids. Additionally, the freeze-dried extract or the cell-free protein synthesis reaction mixture can contain the template nucleic acid encoding the target protein.
Overall, this patent describes a freeze-dried bacterial extract that can be used for efficient and long-term cell-free protein synthesis. The extract's specific carbohydrate composition and low residual water content contribute to its stability and protein synthesis activity. The methods outlined in the patent provide a way to produce target proteins, including those with non-natural amino acids, using the freeze-dried extract and a cell-free protein synthesis reaction mixture.
To know more about GlobalData’s detailed insights on Sutro Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
